22.36
price up icon1.36%   0.30
pre-market  Vorhandelsmarkt:  22.46   0.10   +0.45%
loading
Schlusskurs vom Vortag:
$22.06
Offen:
$21.8
24-Stunden-Volumen:
717.51K
Relative Volume:
0.74
Marktkapitalisierung:
$1.48B
Einnahmen:
$9.98M
Nettoeinkommen (Verlust:
$-154.08M
KGV:
-8.6667
EPS:
-2.58
Netto-Cashflow:
$-159.66M
1W Leistung:
-2.14%
1M Leistung:
+9.07%
6M Leistung:
-7.76%
1J Leistung:
-38.47%
1-Tages-Spanne:
Value
$21.71
$22.67
1-Wochen-Bereich:
Value
$21.71
$23.40
52-Wochen-Spanne:
Value
$14.40
$47.00

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Firmenname
Celldex Therapeutics Inc
Name
Telefon
908-200-7500
Name
Adresse
53 FRONTAGE ROAD, HAMPTON
Name
Mitarbeiter
186
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
CLDX's Discussions on Twitter

Vergleichen Sie CLDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CLDX
Celldex Therapeutics Inc
22.36 1.52B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-28 Eingeleitet Canaccord Genuity Buy
2025-03-20 Eingeleitet Morgan Stanley Overweight
2025-02-13 Eingeleitet UBS Buy
2024-10-07 Eingeleitet Citigroup Buy
2024-09-30 Eingeleitet Goldman Neutral
2024-09-27 Herabstufung Wolfe Research Outperform → Peer Perform
2024-06-18 Eingeleitet Stifel Buy
2024-06-11 Eingeleitet Wolfe Research Outperform
2023-12-20 Eingeleitet TD Cowen Outperform
2023-11-10 Hochstufung Wells Fargo Underweight → Equal Weight
2023-08-22 Eingeleitet Wells Fargo Underweight
2021-09-17 Eingeleitet Jefferies Buy
2021-09-10 Eingeleitet SVB Leerink Outperform
2021-07-22 Eingeleitet Guggenheim Buy
2020-02-21 Eingeleitet Cantor Fitzgerald Overweight
2017-08-01 Fortgesetzt H.C. Wainwright Buy
2016-11-07 Eingeleitet Aegis Capital Buy
2016-03-08 Herabstufung Jefferies Buy → Hold
2016-03-07 Herabstufung Guggenheim Buy → Neutral
2016-03-07 Herabstufung Leerink Partners Outperform → Mkt Perform
2016-03-07 Herabstufung Wedbush Outperform → Neutral
2016-03-01 Eingeleitet H.C. Wainwright Buy
2015-08-11 Bestätigt Brean Capital Buy
2015-08-11 Bestätigt Oppenheimer Outperform
2015-08-11 Bestätigt ROTH Capital Buy
2015-06-02 Bestätigt WBB Securities Strong Buy
2014-11-17 Bestätigt ROTH Capital Buy
2014-03-04 Bestätigt Oppenheimer Outperform
2013-07-08 Bestätigt Cantor Fitzgerald Buy
2013-03-08 Bestätigt Cantor Fitzgerald Buy
2013-02-26 Bestätigt Oppenheimer Outperform
2013-01-10 Bestätigt Cantor Fitzgerald Buy
2012-10-02 Bestätigt Oppenheimer Outperform
2012-09-14 Bestätigt Cantor Fitzgerald Buy
Alle ansehen

Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Celldex Therapeutics Inc. a good long term investmentExceptional market positioning - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Celldex Therapeutics Inc. Stock Analysis and ForecastOutstanding risk-reward balance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Celldex Therapeutics Inc. stockMarket-beating returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Celldex Therapeutics Inc. stock priceDynamic profit expansion - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Is Celldex Therapeutics Inc. stock a good hedge against inflationFree Stock Market Trend Analysis - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Celldex Therapeutics Inc. stock price move sharplySafety First Trading Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Celldex Therapeutics Inc. stock attracts strong analyst attention2x Return Forecast - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Celldex Therapeutics Inc. stock performs during market volatility2x Return Forecast - beatles.ru

Jul 15, 2025
pulisher
Jul 08, 2025

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Jul 08, 2025
pulisher
Jul 03, 2025

B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, - openPR.com

Jul 03, 2025
pulisher
Jun 27, 2025

Cholera Vaccines Market Deep Research and Growth in Future Scope - openPR.com

Jun 27, 2025
pulisher
Jun 25, 2025

Is Celldex Therapeutics, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

(06/24/25) CLDX: A Promising Biotech Name Targeting CSU - moneyshow.com

Jun 24, 2025
pulisher
Jun 23, 2025

Chronic spontaneous urticaria improvements persist 28 weeks after barzolvolimab stopped - Healio

Jun 23, 2025
pulisher
Jun 16, 2025

Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World

Jun 16, 2025
pulisher
Jun 15, 2025

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded - Asianet Newsable

Jun 15, 2025
pulisher
Jun 15, 2025

Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from HC Wainwright - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 - MarketScreener

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term - GlobeNewswire

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire Inc.

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Targ - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics Inc (CLDX) Stock: A Comprehensive 52-Week Review - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex shares jump on impressive skin disorder drug data By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News

Jun 13, 2025
pulisher
Jun 13, 2025

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex stock maintains Overweight rating on promising CSU therapy results By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire

Jun 13, 2025

Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):